Retatrutide: Research, Studies & Structure

What is Retatrutide?

Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.

Biological role or research focus

GLP-1, GIP, and glucagon receptor research.

“R”, “Reta”, and “GLP-3” are candidate seller shorthand, not verified product identities.

Role reference: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Names you may encounter

LY3437943 · GLP-3 · reta

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity: GLP-1 / GIP / glucagon receptor agonist
Main research area: Investigational metabolic therapy
Evidence featured: Human phase 2 trial
Source check: October 4, 2026

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Molecular structure

⤢ Enlarge 2D

Sequence & modification mapA sequence and modification map based on the NIH GSRS definition. Aib replaces residues 2 and 20; residue 13 is alpha-methyl-leucine; Lys17 carries a lipid side chain. This is not a bond-by-bond drawing or 3D fold.NIH GSRS · NOP2Y096GV ↗

Mechanism & research rationale

It engages GLP-1, GIP, and glucagon receptors in one molecule. Clinical trials test the combined effects rather than assuming that adding receptor targets guarantees better outcomes.

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Research context & status

This profile presents investigational obesity evidence. FDA’s unapproved-GLP-1 information states that retatrutide is not a component of an FDA-approved drug. Study reports should be dated and distinguished from approval announcements.

Source: FDA · Unapproved GLP-1 products ↗

What does the evidence show?

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human phase 2 trial · 2023

Triple-receptor obesity trial

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Population / model: 338 adults with obesity, or overweight with a weight-related condition.
Study design: Forty-eight-week randomized, blinded, placebo-controlled study; primary endpoint at 24 weeks.
Main finding: At 48 weeks, average weight reduction reached 24.2% in the highest studied group versus 2.1% with placebo. Gastrointestinal events and dose-related heart-rate increases were reported.
Limits & context: This early efficacy trial does not establish long-term outcomes or verify commercial “R” products. Study doses describe the trial, not instructions for using research chemicals.

Read PubMed abstract ↗Publisher paper ↗

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

Human randomized trial · 2023

Phase 2 trial in type 2 diabetes

What did the separate diabetes trial add to the obesity findings?

Population / model: 281 adults with type 2 diabetes randomized; 275 included in efficacy analyses.
Study design: Double-blind phase 2 study with placebo and dulaglutide 1.5 mg comparators. Primary endpoint: HbA1c change at 24 weeks; follow-up continued to 36 weeks.
Main finding: At 24 weeks, mean HbA1c reductions ranged from 0.43 to 2.02 percentage points across retatrutide groups, versus 0.01 with placebo and 1.41 with dulaglutide. All but the lowest retatrutide group outperformed placebo on that endpoint. Gastrointestinal adverse events were reported.
How to read it: This study supports a glucose-control research question in diabetes; it is separate from the 338-participant obesity study.
Limits & context: Phase 2 size and duration limit conclusions about uncommon harms and long-term outcomes. Not every retatrutide group outperformed the active comparator. Trial findings do not authenticate coded “R” seller listings. Funded by Eli Lilly.

Read PubMed abstract ↗Publisher paper ↗

Source: Rosenstock et al. · The Lancet · 2023 ↗

Human phase 3 randomized trial · 2026

TRIUMPH-1 phase 3 obesity trial

Do the phase 2 weight results hold up in a large, longer trial, and what happens to knee pain and sleep apnea?

Population / model: 2,339 adults with obesity and without diabetes, including 574 with knee osteoarthritis and 243 with obstructive sleep apnea.
Study design: Randomized, double-blind, placebo-controlled phase 3 trial of once-weekly retatrutide at three dose levels for 80 weeks. Primary outcomes: percent weight change, knee-pain score in the osteoarthritis subgroup, and breathing interruptions per hour in the sleep apnea subgroup.
Main finding: Average weight change was -17.6%, -23.7% and -25.0% across the three retatrutide groups versus -3.9% with placebo. Knee pain and sleep apnea events improved more than with placebo in their subgroups. Gastrointestinal events were the most common adverse events.
How to read it: TRIUMPH-1 confirms the scale of phase 2 weight loss in a population about seven times larger, followed for 80 weeks.
Limits & context: Funded by Eli Lilly. Eighty weeks cannot show long-term safety, weight maintenance after stopping, or effects on heart attacks and strokes. Retatrutide remained investigational when checked, and trial results do not verify any seller listing.

Read PubMed abstract ↗Publisher paper ↗

Source: TRIUMPH-1 · N Engl J Med · 2026 ↗

Human phase 3 randomized trial · 2026

TRIUMPH-2 phase 3 trial in type 2 diabetes

How much weight do adults with type 2 diabetes lose on retatrutide over 80 weeks?

Population / model: 1,152 adults with overweight or obesity (BMI 27 or higher) and type 2 diabetes at 92 centers in eight countries; mean age 55.
Study design: Randomized, double-blind, placebo-controlled phase 3 trial of once-weekly retatrutide at three dose levels for 80 weeks. Primary outcome: percent weight change.
Main finding: Average weight change was -11.9%, -16.8% and -18.8% across the three retatrutide groups versus -5.1% with placebo, and 84% of participants completed the study drug. Gastrointestinal events were the most frequent adverse events.
How to read it: Weight loss was smaller than in people without diabetes, a pattern also seen with other incretin medicines.
Limits & context: Funded by Eli Lilly. Long-term safety and cardiovascular outcomes need separate trials, and results describe the manufacturer’s study drug only.

Read PubMed abstract ↗Publisher paper ↗

Source: TRIUMPH-2 · The Lancet · 2026 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Related records in our PubMed snapshot

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. ↗
Rapid communications in mass spectrometry : RCM · Issue date 2026 Dec 15 · Not appraised

The First Triple Agonist for Antiobesity: Retatrutide. ↗
Cardiology in review · Issue date 2026 Nov-Dec 01 · Not appraised

Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. ↗
Behavioural brain research · Issue date 2026 Oct 2 · Not appraised

Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest. ↗
BMJ (Clinical research ed.) · Issue date 2026 Oct 1 · Not appraised

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. ↗
The New England journal of medicine · Issue date 2026 Sep 29 · Not appraised

Search additional PubMed records ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Safety & precautions

Safety evidence & remaining uncertainty

Gastrointestinal effects and heart-rate changes appeared in the phase 2 trial. That study cannot establish every long-term risk or the identity and safety of a vendor vial.

Source: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

What are people discussing?

Fouad Abiad Media

Comparing metabolic peptides in conversation

The speakers compare personal experiences and describe differences among semaglutide, tirzepatide, and retatrutide. Their tolerability anecdotes are not a head-to-head clinical trial.

Question to take to the evidence

Does a comparative trial support the claimed difference in effectiveness or adverse effects?

▶ Watch 10:38–12:06 ↗

Caption excerpt reviewed · Claims not independently verified · 2026-10-04
Original episode: RETATRUTIDE: EVERYTHING YOU NEED TO KNOW | Wes Christensen | Fouad Abiad's Real Bodybuilding Podcast

Watch the source discussions

170 matching video records · 7 with captions indexed.

Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.